PRIMECAP Odyssey Discovery ETF
POMG - ETF AI Analysis
Top Page
PRIMECAP Odyssey Discovery ETF (POMG)
POMG, the PRIMECAP Odyssey Discovery ETF, earns a solid overall rating largely because it holds innovative companies like BioMarin Pharmaceutical and Elanco Animal Health, which combine strong financial performance, strategic growth moves, and positive business momentum. At the same time, weaker names such as Xometry and Septerna, which face profitability and cash flow challenges, weigh on the fund’s quality. The main risk factor is the fund’s exposure to several companies with ongoing profitability and valuation concerns, which could add volatility for investors.
POMG vs. SPDR S&P 500 ETF (SPY)
- AUM
- 69.70M
- Region
- North America
- Expense Ratio
- 0.68%
- Beta
- N/A
- Issuer
- PrimeCap
- Inception Date
- Oct 20, 2026
- Dividend Yield
- N/A
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
POMG Summary
PRIMECAP Odyssey Discovery ETF (POMG) is a U.S. stock fund that focuses on smaller and mid-sized companies, aiming for long-term growth beyond the biggest household-name firms. It doesn’t track a specific index, but follows an “extended market” theme, spreading investments across health care, technology, industrials, and other sectors. Well-known holdings include MongoDB and BioMarin Pharmaceutical, giving investors exposure to innovative, fast-growing businesses that can complement a large-cap portfolio. A key risk is that smaller companies can be more volatile, so the fund’s value can rise and fall sharply with changes in the stock market.
How much will it cost me?
This ETF has an expense ratio of 0.68%, which means you’ll pay about $6.80 per year for every $1,000 you invest. That’s higher than the average index ETF because this fund is actively managed, with managers selecting specific mid- and small-cap stocks rather than just tracking a simple market index.
What would affect this ETF?
This ETF is heavily invested in U.S. mid- and small-cap health care, technology, and industrial companies, so breakthroughs in biotech, software, and manufacturing, along with a strong U.S. economy, could support future growth for holdings like Xometry, Universal Display, and MongoDB. On the other hand, higher interest rates, weaker economic conditions, or tighter regulations on drug development and tech companies could hurt smaller, growth-focused firms such as GRAIL, BridgeBio Pharma, and Glaukos, making the fund more volatile.
POMG Top 10 Holdings
This ETF is leaning heavily into U.S. mid- and small-cap health care and tech, with Glaukos, Septerna, and GRAIL acting as the main growth engines thanks to their rising momentum and upbeat pipelines. Xometry and Entegris add a punchy industrial-tech flavor, with Xometry climbing steadily and Entegris contributing more mixed but still supportive returns. On the weaker side, Universal Display and MongoDB have been lagging lately, losing some steam and tempering overall gains. The result is a concentrated bet on innovative U.S. growth stories, especially in health care and niche technology.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 XMTR | Xometry | 5.16% | $3.52M | $6.63B | 85.34% | 55Neutral |
 GRAL | GRAIL Inc | 3.60% | $2.46M | $5.46B | 51.69% | 70Outperform |
 OLED | Universal Display | 3.51% | $2.39M | $3.98B | -34.75% | 66Neutral |
 GKOS | Glaukos | 3.09% | $2.11M | $13.28B | 174.37% | 61Neutral |
 ELAN | Elanco Animal Health | 3.09% | $2.11M | $12.86B | 19.61% | 69Neutral |
 BBIO | BridgeBio Pharma | 3.04% | $2.07M | $14.47B | 18.43% | 59Neutral |
 SEPN | Septerna, Inc. | 2.70% | $1.84M | $2.28B | 159.84% | 61Neutral |
 BAH | Booz Allen | 2.49% | $1.70M | $10.12B | -0.26% | 65Neutral |
 BMRN | BioMarin Pharmaceutical | 2.45% | $1.67M | $10.85B | 8.08% | 75Outperform |
 LUV | Southwest Airlines | 2.44% | $1.66M | $21.76B | 41.07% | 66Neutral |
POMG Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For POMG, the sentiment is Positive. The current price of 26.58 is compared to the 20-day moving average (MA) of , compared to the 50-day MA of , and compared to the 200-day MA of , indicating a neutral trend. The MACD of indicates Neutral momentum. The RSI at is Neutral, neither overbought nor oversold. The STOCH value of 59.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for POMG.
POMG Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| POMG | $26.58 | $30.00(12.87% Upside) | $69.70M | 0.68% | 66Neutral |
 OASC | $32.71 | $40.11(22.61% Upside) | $97.22M | 0.69% | 68Neutral |
 MYLD | $32.86 | $36.99(12.56% Upside) | $53.83M | 0.62% | 68Neutral |
 BCSM | $24.30 | $30.18(24.21% Upside) | $35.82M | 0.75% | 58Neutral |
 IVSS | $29.83 | $36.13(21.13% Upside) | $29.97M | 0.59% | 68Neutral |
 BRSM | $24.91 | $30.55(22.65% Upside) | $26.79M | 0.38% | 66Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| POMG | PRIMECAP Odyssey Discovery ETF | 26.58 | 1.06 | 4.15% | |
| OASC | OneAscent Small Cap Core ETF | 32.71 | 3.99 | 13.88% | |
| MYLD | Cambria Micro and SmallCap Shareholder Yield ETF | 32.86 | 7.83 | 31.30% | |
| BCSM | Baron SMID Cap ETF | 24.30 | -0.01 | -0.03% | |
| IVSS | Applied Finance IVS US SMID ETF | 29.83 | 4.61 | 18.28% | |
| BRSM | MFS Blended Research Small-Mid Cap ETF | 24.91 | -0.13 | -0.51% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.